Documentos para Download:

• PDF Mieloma Múltiplo - Tratamento (Parte I)
• PDF Diagnóstico, prevenção e tratamento de complicações tromboembólicas na covid-19
• PDF Trombocitemia essencial – critério sistema prognóstico
• PDF Policitemia vera alvo de hematócrito
• PDF Policitemia vera - Agentes Citoredutores
• PDF Policitemia vera - Antiagreção Plaquetária
• PDF Policitemia vera - Sistema Prognóstico
• PDF Doenças Mieloproliferativas - Critério diagnóstico
• PDF Doenças Mieloproliferativas - Papel da Biópsia de Medula Óssea
• PDF Doenças Mieloproliferativas - Papel das mutações no diagnóstico
• PDF Mielofibrose Primária - Critério sistema prognóstico
• PDF Mielofibrose Primária - Papel da Eritropoetina
• PDF Mielofibrose Primária - Papel da Hidroxiureia
• PDF Mielofibrose Primária - Papel das mutações no prognóstico
• PDF Mielofibrose Primária - Papel do Interferon
• PDF Mielofibrose Primária - Papel dos Corticosteroides
• PDF Mielofibrose Primária - Papel dos Imunomoduladores
• PDF Mielofibrose Primária - Tratamento com inibidores da Jak
• PDF Mielofibrose Primária - Pré-Fibrótica e Trombocitemia Essencial - Diagnóstico diferencial
• PDF Anemia Falciforme - Doppler Transcraniano na prevenção de AVC
• PDF Anemia Falciforme - Transfusão de concentrado de hemácias e prevenção primária de Acidente Vascular Cerebral
• PDF Anemia Falciforme - transfusão de concentrado de hemácias e prevenção secundária de Acidente Vascular Cerebral
• PDF Anemia Falciforme - Hidroxiureia e prevenção primária de AVC
• PDF Síndromes Mielodisplásicas - Exames Necessários Para Confirmação
• PDF Síndromes Mielodisplásicas - Sistema De Classificação
• PDF Síndromes Mielodisplásicas - Tratamento De Alto Risco
• PDF Síndromes Mielodisplásicas - Tratamento De Baixo Risco Com Deleção 5q
• PDF Síndromes Mielodisplásicas - Tratamento De Baixo Risco Sem Deleção 5q
• PDF Transfusão De Hemácias - Prognóstico De Pacientes Com Recusa
• PDF Trombocitemia Essencial - Mutações No Prognóstico
• PDF Trombocitemia Essencial - Terapêutica
• PDF Trombocitopenia Imune (PTI) - Adultos
• DIR 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura
• DIR Acute leukemia
• DIR Acute Myeloid Leukemia
• DIR Alfadamoctocogue pegol — Profilaxia secundária em pacientes com Hemofilia A, a partir de 12 anos, previamente tratados e sem inibidor
• DIR Alfaefmoroctocogue (fator VIII de coagulação recombinante Fc) — Indução de imunotolerância em pacientes com hemofilia A e inibidores
• DIR Alfaeftrenonacogue — Hemofilia B
• DIR Alfaepoetina — Doença falciforme apresentando declínio da função renal e piora dos níveis de hemoglobina
• DIR Alfalonoctocogue — Adultos e adolescentes (acima de 12 anos) com hemofilia A previamente tratados e sem inibidor, para profilaxia secundária
• DIR Alfanonacogue — Hemofilia B em pacientes menores de 19 anos de idade
• DIR Alfarurioctocogue pegol — Tratamento de pacientes com hemofilia A
• DIR American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism
• DIR American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
• DIR American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
• DIR American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients
• DIR American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism
• DIR American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy
• DIR American Society of Hematology 2019 guidelines for immune thrombocytopenia
• DIR American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients
• DIR American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease
• DIR American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
• DIR American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain
• DIR American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults
• DIR American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support
• DIR American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
• DIR American Society of Hematology 2021 Guidelines for Management of Venous Thromboembolism: Prevention and Treatment in Patients with Cancer.
• DIR American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
• DIR American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing
• DIR American Society of Hematology Guidelines on Acute Lymphoblastic Leukemia in Adolescents and Young Adults
• DIR American Society of Hematology guidelines on Amyloidosis
• DIR Ampliação do Transplante de Células - Tronco Hematopoiéticas — Mucopolissacaridose Tipo I
• DIR Ampliação do Transplante de Células- Tronco Hematopoiéticas — Mucopolissacaridose Tipo II
• DIR Anemia Deficiencia de Ferro
• DIR Anemia Hemolítica Autoimune
• DIR Anemia na Doença Renal Crônica - DRC
• DIR Antirretroviral zidovudina — Leucemia/linfoma de células T associado ao HTLV-1
• DIR Asciminibe — Adultos com leucemia mieloide crônica cromossomo Philadelphia positivo
• DIR ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in Latin America
• DIR ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America
• DIR ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, SVH, 2022 Guidelines for diagnosis of Venous Thromboembolism and management in Special Populations in Latin America
• DIR Assessment & Management of Common Anaemias In Adults
• DIR Blinatumomabe
• DIR Blinatumomabe — Leucemia linfoblástica aguda (LLA) B derivada pediátrica em primeira recidiva medular de alto risco
• DIR Blinatumomabe — Pacientes adultos com leucemia linfoblástica aguda de células B, cromossomo Philadelphia negativo, com doença residual mínima positiva, que atingiram a remissão completa.
• DIR Blinatumomabe — Pacientes adultos com leucemia linfoblástica aguda de células B, cromossomo Philadelphia negativo e com doença recidivada ou refratária
• DIR Blood transfusion
• DIR Blood transfusion
• DIR Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
• DIR Bortezomibe — Mieloma múltiplo em pacientes adultos, não previamente tratados, elegíveis ao transplante autólogo de células-tronco hematopoiéticas
• DIR Bortezomibe — Mieloma múltiplo em pacientes adultos, não previamente tratados, inelegíveis ao transplante autólogo de células-tronco hematopoiéticas
• DIR Bortezomibe — Mieloma múltiplo em pacientes adultos previamente tratados
• DIR Bosutinibe — Segunda linha de pacientes com leucemia mieloide crônica com cromossomo Philadelphia positivo com resistência ou intolerância a pelo menos uma terapia prévia, incluindo imatinibe
• DIR Brentuximabe vedotina — Adultos com linfoma de hodgkin cd30+ refratário ou recidivado após transplante autólogo de células-tronco
• DIR Carboximaltose férrica — Tratamento de pacientes adultos com anemia por deficiência de ferro e intolerância ou contraindicação aos sais orais de ferro
• DIR Carfilzomibe — Mieloma múltiplo recidivado ou refratário que receberam uma terapia prévia
• DIR Carfilzomibe — Tratamento de pacientes com mieloma múltiplo recidivado ou refratário, que receberam terapia prévia
• DIR Chronic leukemia
• DIR Common anemias in adults
• DIR Concizumabe — Hemofilia B moderada a grave com inibidores com idade a partir de 12 anos
• DIR COVID-19 rapid guideline: haematopoietic stem cell transplantation
• DIR COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)
• DIR Dabigatrana — Prevenção de acidente vascular cerebral e do idarucizumabe para reversão do efeito anticoagulante da dabigatrana
• DIR Dapsona — Adultos com púrpura trombocitopênica idiopática primária refratária ou dependente de corticosteroide
• DIR Dapsona — Púrpura trombocitopênica idiopática refratária, crônica ou dependente de corticosteroide em crianças e adolescentes
• DIR Daratumumabe em combinação com bortezomibe e dexametasona — Mieloma múltiplo recidivado e/ou refratário que receberam uma única terapia prévia no Sistema Único de Saúde (SUS)
• DIR Daratumumabe em monoterapia ou associado à terapia antineoplásica — Controle do mieloma múltiplo recidivado ou refratário
• DIR Dasatinibe — Adultos com leucemia linfoblástica aguda cromossomo Philadelphia positivo resistentes/Intolerantes ao mesilato de imatinibe
• DIR Deferiprona — Sobrecarga de ferro em pacientes com doença falciforme
• DIR Derisomaltose férrica — Adultos com anemia por deficiência de ferro, independente da causa, após falha terapêutica, intolerância ou contraindicação aos sais de ferro oral
• DIR Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
• DIR Diretrizes Diagnósticas e Terapêuticas — Mesilato de Imatinibe no Tratamento da Leucemia Linfoblástica Aguda Cromossoma Philadelphia Positivo de Crianças e Adolescentes
• DIR Diretrizes Diagnósticas e Terapêuticas — Mesilato de Imatinibe no Tratamento da Leucemia Linfoblástica Aguda Cromossoma Philadelphia Positivo do Adulto
• DIR Diretrizes Diagnósticas e Terapêuticas — Mieloma Múltiplo
• DIR Doença Falciforme
• DIR Economic analysis of peripherally inserted central venous catheters (PICC), inserted by nursing staff, in cancer and hematological patients
• DIR EFNS guideline on the treatment of cerebral venous and sinus thrombosis
• DIR EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients
• DIR Eltrombopague — Tratamento adicional a imunossupressor em pacientes adultos com anemia aplástica grave
• DIR Eltrombopague olamina — Púrpura trombocitopênica idiopática (PTI)
• DIR Emicizumabe
• DIR Emicizumabe — Até 12 anos de idade com hemofilia A, moderada ou grave, sem inibidores do Fator VIII
• DIR Emicizumabe — Hemofilia A, moderada ou grave, e anticorpos inibidores do Fator VIII, sem restrição de faixa etária.
• DIR Emicizumabe — Hemofilia A e inibidores ao fator VIII refratários ao tratamento de imunotolerância
• DIR Emicizumabe — Hemofilia A grave ou com nível de atividade de fator VIII inferior a 2%, sem anticorpos inibidores do fator VIII, com até 6 anos de idade no início do tratamento.
• DIR Enoxaparina 60 mg/0,6 mL injetável — Prevenção de tromboembolismo venoso em gestantes com trombofilia
• DIR Eritropoietina — Doença falciforme
• DIR ESCMID Guidelines for management of infectious complications after chimeric antigen receptor T cell therapy and bispecific antibodies for haematological malignancies
• DIR European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology
• DIR Evaluation of Minimal Residual Disease in Acute Lymphoblastic Leukemia
• DIR Fator VIII de origem recombinante — Profilaxia primária e tratamento de pacientes com hemofilia A
• DIR Ferripolimaltose — Anemia por deficiência de ferro e intolerância ao sulfato ferroso
• DIR Follow-up Care for Survivors of Lymphoma who have Received Curative-Intent Treatment 26-5
• DIR Ganciclovir intravenoso — Profilaxia e terapia preemptiva para infecção e doença por citomegalovírus (CMV) e tratamento da doença por CMV após transplante de órgão sólidos (TOS) e transplante de células-tronco hematopoiéticas (TCTH)
• DIR Graduated Compression Stockings for the Prevention of Post-operative Venous Thromboembolism (Best Practice 5(2))
• DIR Graduated compression stockings for the prevention of post-operative venous thromboembolism (Best Practice 12(4))
• DIR Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)
• DIR Guideline on haemoglobin cutoffs to define anaemia in individuals and populations
• DIR Haematological cancers
• DIR Haematological cancers: improving outcomes
• DIR Hemofilia A – Uso do Emicizumabe (Protocolo de Uso)
• DIR Hidroxiureia — Crianças com doença falciforme
• DIR Hidroxiureia — Doença falciforme com 2 anos ou mais
• DIR Hidroxiureia 100 mg — Doença falciforme a partir dos 9 meses de idade
• DIR Hidroxiureia 500 mg — Doença Falciforme
• DIR Hidroxiureia 1000 mg — Doença falciforme a partir dos 9 meses de idade
• DIR Ibrutinibe — Leucemia linfocítica crônica recidivada/refratária inelegível a análogos de purina
• DIR Imunoglobulina humana pó liofilizado para solução injetável ou solução injetável na concentração de 3 g ou 6 g — Anemia hemolítica autoimune
• DIR Imunoglobulina humana pó liofilizado para solução injetável ou solução injetável na concentração de 3 g ou 6 g — Púrpura trombocitopênica idiopática
• DIR Indução de Imunotolerância para Indivíduos com Hemofilia A e Inibidor
• DIR Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline
• DIR Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists (CAP) and American Society of Hematology (ASH)
• DIR International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology
• DIR ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura
• DIR ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura
• DIR Laboratory Workup of Lymphoma in Adults: Guideline from the American Society for Clinical Pathology (ASCP) and the College of American Pathologists (CAP)
• DIR Lenalidomida — Mieloma múltiplo recém-diagnosticados que foram submetidos ao transplante de células-tronco
• DIR Lenalidomida — Pacientes com mieloma múltiplo inelegíveis ao transplante de células-tronco hematopoiéticas
• DIR Lenalidomida — Terapia de manutenção em pacientes com mieloma múltiplo submetidos ao transplante de células-tronco hematopoiéticas
• DIR Lenalidomida em combinação com rituximabe — Linfoma folicular previamente tratados
• DIR Letermovir — Profilaxia de infecção e doença causadas pelo citomegalovírus (CMV) em adultos receptores soropositivos para CMV (R+) submetidos ao transplante de células-tronco hematopoiéticas alogênico
• DIR Leucemia Linfoblástica Aguda Cromossoma Philadelphia Positivo de Crianças e Adolescentes (DDT)
• DIR Leucemia Linfoblástica Aguda Ph+ de Adulto com Mesilato de Imatinibe (DDT)
• DIR Leucemia Mieloide Aguda de Crianças e Adolescentes - Diretrizes Diagnósticas e Terapêuticas
• DIR Leucemia Mieloide Aguda do Adulto - Diretrizes Diagnósticas e Terapêuticas
• DIR Leucemia Mieloide Crônica de Criança e Adolescente
• DIR Leucemia Mieloide Crônica do Adulto
• DIR Linfoma de Hodgkin no Adulto
• DIR Linfoma Difuso de Grandes Células B
• DIR Linfoma Folicular
• DIR Low molecular weight heparins versus traditional heparins in thromboembolic diseases
• DIR Luspatercepte — Adultos com anemia dependente de transfusão
• DIR Malignant lymphomas. National consensus-based nutrition guideline
• DIR Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
• DIR Management of Early-Stage Hodgkin Lymphoma 6-20v2
• DIR Management of Haemophilia
• DIR Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
• DIR Management of Transfusion Dependent Thalassaemia
• DIR Marstacimabe — Adultos e adolescentes (≥ 12 anos de idade, acima de 35kg) com hemofilia B grave sem inibidores contra o fator IX de coagulação plasmático
• DIR Mieloma Múltiplo (DDT)
• DIR Molgramostrim 300mcg injetável — Anemia aplástica
• DIR Multiple myeloma
• DIR Myeloma: diagnosis and management
• DIR Nadroparina — Tromboembolia pulmonar de repetição
• DIR Non-Hodgkin lymphoma: diagnosis and management
• DIR Penicilina oral — Profilaxia de infecção em crianças menores de 5 anos com doença falciforme
• DIR PET-CT — Estadiamento e avaliação da resposta ao tratamento do linfoma de Hodgkin e linfoma não Hodgkin
• DIR PET Imaging in Lymphoma 12
• DIR Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
• DIR Ponatinibe — Leucemia mieloide crônica em que houve falha de inibidores de tirosinoquinase de segunda geração
• DIR Ponatinibe — Resgate de pacientes com leucemia mieloide crônica em que houve falha aos inibidores de tirosina quinase de segunda geração
• DIR Positron Emission Tomography in Hodgkin Lymphoma Patients Undergoing Curative-Intent Treatment 27-4
• DIR Prevention and management of venous thromboembolism (SIGN CPG 122)
• DIR Prevention and Treatment of Venous Thromboembolism
• DIR Procedimentos de transplante de células-tronco hematopoéticas (TCTH) alogênico — Ampliar a idade máxima para 75 anos
• DIR Profilaxia primária em caso de Hemofilia Grave (Protocolo de Uso)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Anemia Hemolítica Autoimune
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Anemia Hemolítica Autoimune
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Anemia na Doença Renal Crônica – Alfaepoetina
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Anemia na Doença Renal Crônica – Reposição de Ferro
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença Falciforme
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença Falciforme
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Leucemia Mieloide Crônica de Crianças e Adolescentes
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Leucemia Mieloide Crônica do Adulto
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Linfoma de Hodgkin no Adulto
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Prevenção de Tromboembolismo Venoso em Gestantes com Trombofilia
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Púrpura Trombocitopênica Idiopática
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Trombocitopenia Imune Primária
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Tromboembolismo Venoso em Gestantes com Trombofilia
• DIR Protocolo de Uso do Blinatumomabe — Blinatumomabe para Leucemia Linfoblástica Aguda (LLA) B Derivada Pediátrica em Primeira Recidiva Medular de Alto Risco
• DIR Protocolo de Uso do Fator VIII da coagulação na imunotolerância — Fator VIII da coagulação na imunotolerância para indivíduos com hemofilia A e inibidor do fator VIII da coagulação sanguínea
• DIR Protocolo de Uso dos Fatores de Coagulação — Fatores de Coagulação para a Profilaxia Primária em caso de Hemofilia Grave
• DIR Protocolo de Uso do Zidovudina — Zidovudina para Tratamento do Adulto com Leucemia/Linfoma Associado ao Vírus HTLV-1
• DIR Protocolo de uso Emicizumabe — Emicizumabe para tratamento de indivíduos com hemofilia A e inibidores do fator VIII refratários ao tratamento de imunotolerância
• DIR Protocolo de Uso Emicizumabe — Emicizumabe para tratamento de indivíduos com hemofilia A moderada e grave e inibidores do fator VIII da coagulação sanguínea
• DIR Reação em cadeia da polimerase – transcriptase reversa (RT-PCR) qualitativa e quantitativa (RT-qPCR) e Hibridização in situ (ISH) — Monitoramento da Leucemia Mieloide Crônica (LMC) e da Leucemia Linfoblástica Aguda cromossoma Philadelphia positivo (LLA Ph
• DIR Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper
• DIR Rituximabe — Adultos com púrpura trombocitopênica idiopática primária refratária ou dependente de corticosteroide
• DIR Rituximabe — Linfoma não Hodgkin de células B, folicular, CD20 positivo
• DIR Rituximabe — Linfoma não hodgkin de células b, folicular, cd20 positivo, em 1ª e 2ª linha
• DIR Rituximabe — Tratamento da púrpura trombocitopênica idiopática refratária, crônica ou dependente de corticosteroide em crianças e adolescentes
• DIR Rituximabe associado à quimioterapia com fludarabina e ciclofosfamida — Primeira linha da leucemia linfocítica crônica
• DIR Rituximabe em monoterapia — Linfoma folicular assintomático, independentemente do estádio inicial
• DIR Rituximabe subcutâneo — Linfoma não Hodgkin de células B, folicular, CD20 positivo não tratado previamente, em combinação com quimioterapia
• DIR Rituximabe subcutâneo — Linfoma não Hodgkin difuso de grandes células B, CD20 positivo em combinação à quimioterapia
• DIR Rituximab in lymphoma and chronic lymphocytic leukemia: A Clinical Practice Guideline.
• DIR Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
• DIR Romiplostim — Adultos com púrpura trombocitopênica idiopática primária refratária ou dependente de corticosteroide
• DIR Romiplostim — Púrpura trombocitopênica idiopática (PTI) crônica e refratária em alto risco de sangramento
• DIR Romiplostim — Púrpura trombocitopênica idiopática refratária, crônica ou dependente de corticosteroide em crianças e adolescentes
• DIR Ruxolitinibe — Mielofibrose primária, mielofibrose pós policitemia vera ou mielofibrose pós trombocitemia essencial, de risco intermediário-2 ou alto
• DIR Ruxolitinibe — Tratamento de pacientes com mielofibrose, risco intermediário-2 ou alto, com plaquetas acima de 100.000/mm3, inelegíveis ao transplante de células-tronco hematopoéticas
• DIR Sickle cell disease
• DIR Sickle cell disease: managing acute painful episodes in hospital
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
• DIR Stem Cell Transplantation in the Treatment of Acute Lymphoblastic Leukemia: Recommendations
• DIR Suplemento alimentar em pó - NutriSUS com múltiplos micronutrientes — Prevenção e controle da anemia ferropriva
• DIR Talidomida no tratamento da Doença Enxerto Contra Hospedeiro e do Mieloma Múltiplo
• DIR Teste citogenético por Hibridização in Situ por Fluorescência (FISH) — Detecção de alterações citogenéticas de alto risco em pacientes com mieloma múltiplo
• DIR The Diagnosis & Management of Anaemias in Children
• DIR The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
• DIR The treatment guidelines for high-risk multiple myeloma
• DIR Transplante alogênico de células-tronco hematopoiéticas de medula óssea — Hemoglobinúria paroxística noturna
• DIR Transplante de células-tronco hematopoéticas alogênico aparentado — Doença falciforme
• DIR Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
• DIR Trióxido de arsênio — Leucemia Promielocítica Aguda (LPA)
• DIR Trióxido de arsênio em primeira linha — Leucemia promielocítica aguda de risco baixo a intermediário
• DIR Trombocitopenia Imune Primária
• DIR Tromboembolismo Venoso em Gestantes com Trombofilia
• DIR Valganciclovir oral — Profilaxia e terapia preemptiva para infecção e doença por citomegalovírus (CMV) e tratamento da doença por CMV após transplante de órgão sólidos (TOS) e transplante de células-tronco hematopoiéticas (TCTH)
• DIR Venetoclax em combinação com azacitidina — Adultos com leucemia mielóide aguda recém-diagnosticada e inelegível à quimioterapia intensiva
• DIR Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
• DIR Venous thromboembolism in adults
• DIR Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
• DIR Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
• DIR Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians
• DIR Venous Thromboembolism Risk Assessment and Prophylaxis: Facilitators and Barriers to Compliance with Clinical Guidelines in Acute Care (Best Practice 17(2))
• DIR Venous thromboembolism treating with the appropriate anticoagulant and duration
• DIR Western Blot e PCR em tempo real — Pacientes com leucemia/linfoma de células T do adulto associado ao HTLV-1
• DIR World Federation of Hemophilia Guidelines for the Management of Hemophilia, 3rd edition

Documentos para Download:

• DIR 2024 Saudi Guideline for Community acquired pneumonia
• DIR AAOS Appropriate Use Criteria for the Prevention of Orthopaedic Infection in Patients Undergoing Dental Procedures
• DIR AAOS Diagnosis and Prevention of Periprosthetic Joint Infections Clinical Practice Guideline
• DIR AAOS Systematic Literature Review on the Management of Surgical Site Infections
• DIR Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home)
• DIR Adalimumabe — Uveítes não infecciosa intermediária, posterior e pan-uveítes ativa
• DIR Adalimumabe — Uveítes não infecciosa intermediária, posterior e pan-uveítes inativa
• DIR Adalimumabe — Uveítes não infecciosas em crianças e adolescentes não associadas à artrite idiopática juvenil
• DIR Ampliação de uso — Exame para tipificação do alelo HLA-B, para pessoas vivendo com HIV/aids (PVHA) com indicação de uso do antirretroviral Abacavir (ABC)
• DIR Analysis of surgical antibiotic prophylaxis
• DIR Analysis of tuberculosis isolation and prophylaxis techniques at a hospital level
• DIR Antibiótico inalatório (tobramicina) — Colonização das vias aéreas em pacientes com fibrose cística
• DIR Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site Infection (2nd Edition)
• DIR Antibiotic surgical prophylaxis of patients colonised by multidrug-resistant bacteria
• DIR Antibiotic surgical prophylaxis regimens among patients colonised by MDR-GNB and MDR-GPB
• DIR Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
• DIR Antimicrobial stewardship
• DIR Antimicrobial stewardship: changing risk-related behaviours in the general population
• DIR Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
• DIR Antirretrovirais (ARV) Didanosina Entérica (ddI EC) 250mg — HIV/Aids
• DIR Antirretrovirais (ARV) Didanosina Entérica (ddI EC) 400mg — HIV/Aids
• DIR Antirretrovirais (ARV) Fosamprenavir (FPV) 700m — HIV/Aids
• DIR Antirretroviral etravirina 200mg — Infecção pelo HIV
• DIR Appraisal of the variability and suitability of prescribing antimicrobials in primary health care in the Basque Country
• DIR Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis
• DIR Australian Guidelines for the Prevention and Control of Infection in Healthcare (2019)
• DIR Banlanivimabe + etesevimabe — Pacientes adultos de alto risco infectados por SARS-CoV-2
• DIR Baricitinibe — Tratamento de pacientes adultos com Covid-19 hospitalizados que necessitam de oxigênio por máscara ou cateter nasal, ou que necessitam de alto fluxo de oxigênio ou ventilação não invasiva
• DIR Bedaquilina — Tuberculose resistentes à rifampicina, multirresistentes e extensivamente resistentes a medicamentos
• DIR Bictegravir + entricitabina + tenofovir alafenamida — Tratamento de pacientes com infecção pelo HIV-1 virologicamente suprimidos e com doença renal crônica
• DIR Bictegravir 50mg/entricitabina 200mg/tenofovir alafenamida 25mg — HIV
• DIR Casirivimabe + imdevimabe — Pacientes de alto risco infectados por SARS-CoV-2
• DIR Casirivimabe + imdevimabe — Pacientes infectados por SARS-CoV-2 não hospitalizados de alto risco
• DIR Ceftriaxona 500mg injetável — Sífilis
• DIR Cellulitis and erysipelas: antimicrobial prescribing
• DIR Cilgavimabe + tixagevimabe — Profilaxia pré-exposição à Covid-19, em indivíduos adultos e pediátricos (com 12 anos de idade ou mais, pesando pelo menos 40 kg)
• DIR Clinical management of COVID-19
• DIR Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America
• DIR Clinical practice guideline for Urinary Tract Infection in Paediatric Population
• DIR Clinical practice guidelines for influenza
• DIR Cloridrato de clindamicina cápsula 300 mg — Malária
• DIR Clostridioides difficile infection: antimicrobial prescribing
• DIR ​Community acquired pneumonia
• DIR Consensus Document for the Diagnosis of Prosthetic Joint Infections: A Joint Paper by the EANM, EBJIS, and ESR (With ESCMID Endorsement)
• DIR Consolidated guidelines on differentiated HIV testing services
• DIR Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring
• DIR Consolidated guidelines on HIV testing services, 2019
• DIR Cough (acute): antimicrobial prescribing
• DIR COVID-19 guideline: Management of the long-term effects of COVID-19 (SIGN CPG 161)
• DIR COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
• DIR COVID-19 rapid guideline: managing COVID-19
• DIR COVID-19 rapid guideline: managing the long-term effects of COVID-19
• DIR COVID-19 rapid guideline: vitamin D (NG187)
• DIR Cultura líquida automatizada — Detecção de micobactérias e teste de sensibilidade aos antimicrobianos utilizados no tratamento da tuberculose
• DIR Darunavir (DRV) — Tratamento da infecção pelo HIV
• DIR Darunavir 800 mg — Pessoas vivendo com HIV em falha virológica ao esquema de primeira linha e sem mutações que conferem resistência ao darunavir (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V ou L89V).
• DIR Darunavir de 600mg, comprimidos revestidos, como terapia antirretroviral — Adultos infectados pelo HIV/Aids
• DIR Defining Breakthrough Invasive Fungal infection-Position Paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology
• DIR Delamanida — Tuberculose multirresistente e tuberculose com resistência extensiva, condicionado a apresentação de dados de vida real
• DIR Desinvestimento do medicamento artemeter — Malária Grave
• DIR Diagnosing and managing disseminated histoplamsosis among people living with HIV
• DIR Diagnosis, Management & Prevention of Infective Endocarditis
• DIR Diagnosis and management of gonorrhoea and syphilis
• DIR Diagnosis and Management of Sepsis
• DIR Dicloridrato de quinina solução injetável 300 mg/mL — Malária
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 1: Uso de oxigênio, intubação orotraqueal e ventilação mecânica
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 2: Tratamento Medicamentoso
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 2: Tratamento Medicamentoso
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 4: Assistência Hemodinâmica e Medicamentos Vasoativos
• DIR Diretrizes Brasileiras — Tratamento Medicamentoso Ambulatorial do Paciente com Covid-19
• DIR Dolutegravir (DTG) — Tratamento da infecção pelo HIV
• DIR Dolutegravir — Coinfectados com HIV e tuberculose
• DIR Dolutegravir 5 mg — Tratamento complementar ou substitutivo em crianças de 2 meses a 6 anos de idade com HIV
• DIR Dolutegravir sódico — 3ª linha de tratamento da infecção pelo HIV (vírus de imunodeficiência humana)
• DIR Doxiciclina 100 mg — Profilaxia pós-exposição na prevenção das infecções sexualmente transmissíveis (ISTs) bacterianas, clamídia e sífilis
• DIR Doxiciclina 100mg comprimidos — Sífilis
• DIR EAN-ESCMID guidelines on the diagnosis and management of encephalitis in adults caused by infection
• DIR EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic
• DIR Early childhood pacifier use in relation to breastfeeding, SIDS, infection and dental malocclusion (Best Practice 9(3))
• DIR Effectiveness and Safety of Influenza Vaccination During Pregnancy (Best Practice 18(13))
• DIR EFNS-ENS guidelines for the use of PCR technology for the diagnosis of infections of the nervous system
• DIR EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults
• DIR epic4: Guidelines for the prevention of healthcare-associated infections
• DIR ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
• DIR ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery
• DIR ESCMID Clinical Guidelines on the Evaluation and Management of a Reported Antibiotic Allergy
• DIR ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2
• DIR ESCMID COVID-19 living guidelines: drug treatment and clinical management
• DIR ESCMID Generic Competencies in Antimicrobial Prescribing and Stewardship: Towards a European Consensus
• DIR ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
• DIR ESCMID guideline for the diagnosis and management of Pneumocystis pneumonia
• DIR ESCMID guideline for the diagnosis and treatment of biofilm infections 2014
• DIR ESCMID guideline on clinician-targeted interventions to optimise treatment for common acute infections in primary care
• DIR ESCMID guidelines for management of invasive group A streptococcal infections in adult and paediatric patients
• DIR ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug‐resistant Gram‐negative bacteria in hospitalized patients
• DIR ESCMID guidelines on dosing of antimicrobials in patients with renal impairment with or without RRT
• DIR ESCMID guidelines on infection Control Strategies and Interventions to prevent Ventilator-associated Pneumonia in adult patients
• DIR ESCMID guidelines on selection and duration of antibiotic treatment in infectious aortitis and vascular graft and endograft infections
• DIR ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the health care setting
• DIR ESCMID Guidelines on Vaccination of Adult Solid-Organ Transplant Recipients
• DIR ESCMID rapid guidelines for assessment and management of long COVID
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Agents Targeting Lymphoid Cells Surface Antigens [I]: CD19, CD20 and CD52)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Intracellular Signaling Pathways: Tyrosine Kinase and mTOR Inhibitors)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Introduction)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Soluble Immune Effector Molecules [I]: Anti-Tumor Necrosis Factor-α Agents)
• DIR European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)
• DIR European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases
• DIR European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
• DIR European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria b...
• DIR European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
• DIR European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection
• DIR European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
• DIR European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists)
• DIR European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease
• DIR European society of Clinical Microbiology and Infectious Diseases guidelines on diagnosis and treatment of brain abscess in children and adults
• DIR Expert Consensus on Competency Enhancement of Pertussis Prevention, Diagnosis and Management For Healthcare Professionals Based on the Concept of Medical-Preventive Integration
• DIR Expert Consensus on Vaccination for Patients Receiving Targeted Immunotherapy
• DIR Flucitosina — Meningite criptocócica e demais formas de neurocriptococose
• DIR Flu vaccination: increasing uptake
• DIR Flu vaccination: increasing uptake
• DIR Focused Guidelines for the Surveillance and Control of Candida Infections in Healthcare Institutions: Addressing Key Clinical Questions
• DIR Fosfato de clindamicina solução injetável 150 mg/mL — Malária
• DIR Fostensavir trometamol 600 mg — Adultos vivendo com HIV multirresistente aos antirretrovirais
• DIR Ganciclovir — Profilaxia e tratamento de infecções pelo citomegalovírus (CMV) em pacientes imunossuprimidos pelo HIV
• DIR Guidance document for prevention of Clostridium difficile infection in acute healthcare settings
• DIR Guideline on management of pneumonia and diarrhoea in children up to 10 years of age
• DIR Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
• DIR Guidelines for HIV post-exposure prophylaxis
• DIR Guidelines for Oropharyngeal Candidiasis in HIV-Negative Individuals
• DIR Guidelines for the clinical management of severe illness from influenza virus infections
• DIR Guidelines for the diagnosis and management of neurological complications of HIV infection
• DIR Guidelines for the management of adult lower respiratory tract infections
• DIR Guidelines for the management of asymptomatic sexually transmitted infections
• DIR Guidelines for the management of symptomatic sexually transmitted infections
• DIR Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection
• DIR Guidelines for the prevention of bloodstream infections and other infections associated with the use of intravascular catheters. Part I
• DIR Guidelines on long-acting injectable cabotegravir for HIV prevention
• DIR Hanseníase
• DIR Healthcare-associated infections
• DIR Healthcare-associated infections: prevention and control (PH36)
• DIR Healthcare-associated infections: prevention and control in primary and community care
• DIR Healthcare workers’ perceptions of risk from exposure to emerging acute respiratory infectious diseases (Best Practice 16(2))
• DIR Hemoperfusion with polymyxin-B for the treatment of abdominal sepsis by Gram-negative bacteria
• DIR Hepatitis B and C testing: people at risk of infection (PH43)
• DIR HIV/AIDS (HIV). Evidence-Based Nutrition Practice Guideline
• DIR HIV testing: encouraging uptake
• DIR HIV testing: increasing uptake among people who may have undiagnosed HIV
• DIR Human and animal bites: antimicrobial prescribing
• DIR Impetigo: antimicrobial prescribing
• DIR Incorporação da pirazinamida 150mg, apresentação dispersível, na Relação Nacional de Medicamentos Essenciais (RENAME) — Tuberculose (TB) causada por Mycobacterium tuberculosis em crianças menores de dez anos ou adultos com dificuldade de deglutição.
• DIR Incorporating Ethics in Clinical Guidelines in Infectious Diseases: A Scoping Review
• DIR Incorporating ethics into infectious disease clinical practice guidelines
• DIR Infection prevention and control
• DIR Insect bites and stings: antimicrobial prescribing
• DIR International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases Dise...
• DIR International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the Europe...
• DIR Isoniazida 300 mg — Infecção latente por Mycobacterium tuberculosis
• DIR Joint EANM/ESNR and ESCMID-endorsed Consensus Document for the Diagnosis of Spine Infection (Spondylodiscitis) in Adults
• DIR Leg ulcer infection: antimicrobial prescribing
• DIR Lignes directrices pour l'évaluation économique des programmes de vaccination au
• DIR Management of Acute Orofacial Infection of Odontogenic Origin in Children
• DIR Management of Dengue Infection in Adults (Third Edition)
• DIR Management of Drug Resistant-Tuberculosis
• DIR Management of HIV infection in Children
• DIR Management of HIV Infection in Pregnant Women
• DIR Management of Post Operative Infectious Endophthalmitis
• DIR Management of short-term indwelling urethral catheters to prevent urinary tract infections (Best Practice 14(12))
• DIR Management of Short Term Indwelling Urethral Catheters to Prevent Urinary Tract Infections (Best Practice 4(1))
• DIR Management of suspected bacterial lower urinary tract infection in adult women (SIGN CPG 160)
• DIR Management of suspected bacterial urinary tract infection in adults (SIGN CPG 88)
• DIR Management of Tuberculosis (3rd Edition)
• DIR Manejo da Infecção pelo HIV em Adultos - Módulo 1
• DIR Manejo da Infecção pelo HIV em Adultos - Módulo 2
• DIR Manejo da Infecção pelo HIV em Crianças e Adolescentes - Módulo 1
• DIR Manejo da Infecção pelo HIV em Crianças e Adolescentes - Módulo 2
• DIR Meningitis (bacterial) and meningococcal disease
• DIR Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
• DIR Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)
• DIR Metotrexato — uveítes não infecciosas e de não incorporar o micofenolato de mofetila para o tratamento de uveítes não infecciosas
• DIR Microbiological disgnosis of bloodstream infections
• DIR Molgramostrim 300mcg injetável — Doença pelo HIV
• DIR Molnupiravir — Pacientes infectados por SARS-CoV-2 não hospitalizados com alto risco de agravamento da doença
• DIR Neonatal infection
• DIR Neonatal infection: antibiotics for prevention and treatment
• DIR Neutropenic sepsis: prevention and management in people with cancer
• DIR Nirmatrelvir/ritonavir — Covid-19 nos seguintes grupos de pacientes com sintomas leves a moderados, que não requerem oxigênio suplementar, independentemente do status vacinal: a) imunocomprometidos com idade ≥ 18 anos (segundo os critérios utilizados para
• DIR Nirmatrelvir/ritonavir — Para o tratamento da Covid-19 para pacientes com sintomas leves a moderados, que não requerem oxigênio suplementar, independentemente do status vacinal e com idade ≥ 65 anos ou imunocomprometidos com idade ≥ 18 anos
• DIR Otitis media (acute): antimicrobial prescribing
• DIR Palivizumabe — Prevenção da infecção pelo vírus sincicial respiratório
• DIR Palivizumabe para a Prevenção da Infecção pelo Vírus Sincicial Respiratório (Protocolo de Uso)
• DIR Penicilina benzantina — Prevenção da sífilis congênita
• DIR Pneumonia (community-acquired): antimicrobial prescribing (NG138)
• DIR Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
• DIR Pneumonia: diagnosis and management
• DIR Pneumonia in adults: diagnosis and management (CG191)
• DIR Podofilotoxina 1,5 mg/g e imiquimode 50 mg/g — Condilomas acuminados decorrentes de infecção por papilomavírus humano (HPV)
• DIR Pretomanida — Tuberculose resistente a medicamentos
• DIR Prevenção da Transmissão Vertical do HIV, Sífilis e Hepatites Virais
• DIR Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics
• DIR Profilaxia Pós-Exposição de Risco (PEP) à Infecção pelo HIV
• DIR Profilaxia Pré-Exposição (PrEP) Oral à Infecção pelo HIV
• DIR Prophylactic strategies to prevent post-intravitreal injection endophthalmitis (PIE): a protocol for a clinical practice guideline
• DIR Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures
• DIR Prostatitis (acute): antimicrobial prescribing
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis (IST)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Infecção pelo HIV (PEP)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Infecções sexualmente transmissíveis
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Adultos
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Adultos: Módulo 1 - Tratamento
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Adultos: Módulo 2 - Coinfecções e Infecções Oportunistas
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Crianças e Adolescentes
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Crianças e Adolescentes Módulo 1 - Diagnóstico, manejo e acompanhamento de crianças expostas ao HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Crianças e Adolescentes Módulo 2: Diagnóstico, manejo e tratamento de crianças e adolescentes vivendo com HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Prevenção da transmissão vertical de HIV, Sífilis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Prevenção da Transmissão Vertical do HIV, Sífilis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Prevenção Transmissão Vertical de HIV, sífilis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Antirretroviral Pós Exposição de Risco de Infecção ao HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pós-Exposição (PEP) de Risco à Infecção pelo HIV, Infecções Sexualmente Transmissíveis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pós-Exposição de Risco (PEP) à Infecção pelo HIV, IST e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pré-Exposição (PrEP) de risco à infecção pelo HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pré-Exposição (PrEP) Oral à Infecção pelo HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia pré-exposição de risco à infecção pelo HIV (Prep)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Uveítes não infecciosas
• DIR Protocolo de Uso Palivizumabe — Palivizumabe para Prevenção da Infecção pelo Vírus Sincicial Respiratório
• DIR Pyelonephritis (acute): antimicrobial prescribing
• DIR Raltegravir — Primeira linha de tratamento de pessoas vivendo com HIV/Aids
• DIR Raltegravir 100 mg granulado — Profilaxia da transmissão vertical do HIV em crianças com alto risco de exposição ao HIV.
• DIR Rational Antibiotic Utilisation in Selected Paediatric Conditions
• DIR Recommendations on the delivery of health services for the prevention and care of sexually transmitted infections
• DIR Reducing sexually transmitted infections
• DIR Rendesivir — Covid-19 hospitalizados com pneumonia e necessidade de suplementação de oxigênio
• DIR Respiratory tract infections (self-limiting): prescribing antibiotics (CG69)
• DIR Responses of caregivers to children under the age of five with fever and living where malaria is endemic (Best Practice 14(6))
• DIR Rifampicina 300 mg + isoniazida 150 mg — Tuberculose sensível
• DIR Rifapentina + isoniazida — Infecção Latente pelo Mycobacterium Tuberculosis (ILTB)
• DIR Ritonavir cápsula gelatinosa (mole) termolábil — Infecção pelo HIV
• DIR Rituals and behaviours in the operating theatre – joint guidelines of the Healthcare Infection Society and the European Society of Clinical Microbiology and Infectious Diseases
• DIR Screening for Carriage of Carbapenem-Resistant Enterobacteriaceae in Settings of High Endemicity: A Position Paper From an Italian Working Group on CRE Infections
• DIR Sepsis: recognition, diagnosis and early management (NG51)
• DIR SEXUALLY TRANSMITTED DISEASES. SITUATION IN THE BASQUE AUTONOMOUS COMMUNITY. EFFECTIVENESS OF PREVENTIVE MEASURES
• DIR Sexually transmitted infections: condom distribution schemes
• DIR Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1)
• DIR Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians
• DIR Sinusitis (acute): antimicrobial prescribing
• DIR Sore throat (acute): antimicrobial prescribing
• DIR Sperm washing in serodiscordant HIV couples for use in assisted human reproduction techniques
• DIR Staying Healthy: Preventing infectious diseases in early childhood education and care services (5th Edition)
• DIR Sulfato de quinina comprimido 500 mg — Malária
• DIR Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
• DIR Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management
• DIR Tafenoquina — Malária por Plasmodium vivax
• DIR Tafenoquina — Malária vivax
• DIR Tafenoquina e teste quantitativo da atividade da enzima glicose-6-fosfato desidrogenase (G6PD) — Malária por Plasmodium vivax
• DIR Teste de dosagem de adenosina deaminase — Diagnóstico precoce de tuberculose extrapulmonar
• DIR Teste de fluxo lateral — Detecção de lipoarabinomanano em urina (LF-LAM) para rastreamento e diagnóstico de tuberculose ativa em pessoas suspeitas vivendo com HIV/AIDS
• DIR Teste de Liberação de Interferon-gama (IGRA) — Detecção de infecção latente pelo Mycobacterium tuberculosis em pacientes com doenças inflamatórias imunomediadas ou receptores de transplante de órgãos sólidos
• DIR Teste de liberação interferon-gama (interferon gamma release assay - IGRA) — Detecção de tuberculose latente em pacientes imunocomprometidos
• DIR Teste diagnóstico, point of care, de Cryptococcal Antigen Lateral Flow Assay (CRAG-LFA) — Detecção de infecção por Cryptococcus e diagnóstico de meningite criptocócica em pessoas vivendo com o vírus da imunodeficiência humana (PVHIV)
• DIR Teste PCR multiplex — Detecção de múltiplos agentes bacterianos, virais e fúngicos, causadores de meningites e encefalites.
• DIR Teste qualitativo in vitro, por amplificação de DNA e hibridização reversa em fita de nitrocelulose — Detecção de Mycobacterium leprae resistente a rifampicina, dapsona ou ofloxacino em pacientes acometidos por hanseníase e com suspeita de resistência a a
• DIR Testes comerciais de sondas em linha — Detecção do complexo Mycobacterium tuberculosis (MTB), de mutações nas regiões determinantes de resistência a rifampicina e isoniazida (1ª linha) e a fluoroquinolonas e aminoglicosídeos (2ª linha)
• DIR Testes ELISA — Diagnóstico de sífilis
• DIR Testes EQl — Diagnóstico de sífilis
• DIR Testes RPR — Diagnóstico de sífilis
• DIR Testes TRUST — Diagnóstico de sífilis
• DIR Teste Xpert MTB/RIF — Diagnóstico de casos novos de tuberculose e detecção de resistência à rifampicina
• DIR The update of the 2021 ESCMID guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli
• DIR Tocilizumabe — Tratamento de pacientes adultos com Covid-19 hospitalizados
• DIR Tuberculosis
• DIR Tuberculosis
• DIR Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services
• DIR Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring
• DIR Updated recommendations on service delivery for the treatment and care of people living with HIV
• DIR Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and HCV diagnostics
• DIR Update of the 2014 ESCMID guidelines for the management of the infection prevention & control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients
• DIR Urinary tract infection (catheter-associated): antimicrobial prescribing
• DIR Urinary tract infection (lower): antimicrobial prescribing
• DIR Urinary tract infection (recurrent): antimicrobial prescribing
• DIR Urinary tract infection in children and young people
• DIR Urinary tract infection in under 16s: diagnosis and management
• DIR Urinary tract infections appropriate diagnosis and antibiotic use for uncomplicated cystitis and pyelonephritis
• DIR Urinary tract infections in adults
• DIR Use of N95, Surgical, or Cloth Masks to Prevent COVID-19 in Health Care and Community Settings: Living Practice Points From the American College of Physicians (Version 1)
• DIR Use of Nebulized Antimicrobials for the Treatment of Respiratory Infections in Invasively Mechanically Ventilated Adults: A Position Paper From the European Society of Clinical Microbiology and Infectious Diseases
• DIR Uveítes não Infecciosas
• DIR Vaccine uptake in the general population
• DIR Vaccine uptake in under 19s
• DIR Vacina adsorvida difteria, tétano e pertussis (acelular) dTpa — Vacinação de gestantes
• DIR Vacina adsorvida hexavalente acelular — Crianças com até 6 anos, 11 meses e 29 dias imunodeprimidas, com condições clínicas especiais ou com risco aumentado de apresentarem eventos adversos
• DIR Vacina adsorvida meningocócica B (recombinante) — Hemoglobinúria Paroxística Noturna (HPN) que utilizem eculizumabe
• DIR Vacina adsorvida meningocócica B recombinante — Prevenção de doença meningocócica do sorotipo B em crianças menores de 1 ano de idade
• DIR Vacina contra HPV — Prevenção de câncer de colo do útero
• DIR Vacina contra influenza — Portadores de DPOC
• DIR Vacina Covid-19 (Pfizer/BioNTech) — Imunização ativa de crianças na faixa etária de 6 meses a 5 anos incompletos para a prevenção da Covid-19, condicionada ao preço do contrato do Ministério da Saúde vigente e à reavaliação da matéria após fixação de preç
• DIR Vacina da Fiocruz [ChAdOx-1 (Vacina Covid-19 recombinante)] e da Pfizer/Wyeth [BNT162b2 (Vacina Covid-19)] — Prevenção da Covid-19
• DIR Vacina dengue tetravalente (atenuada) — Prevenção de infecção causada pelo vírus da dengue e suas complicações.
• DIR Vacina herpes-zóster — Prevenção do herpes-zóster em idosos com idade ≥ 80 anos e indivíduos imunocomprometidos com idade ≥ 18 anos.
• DIR Vacina Influenza trivalente de alta dose — Prevenção da gripe em idosos com idade maior ou igual a 80 anos
• DIR Vacina meningocócica ACWY (conjugada) — Adolescentes de 11 e 12 anos no Calendário Nacional de Vacinação
• DIR Vacina meningocócica ACWY (conjugada) — Hemoglobinúria Paroxística Noturna (HPN) que utilizem eculizumabe
• DIR Vacina pneumocócica 23-valente — Imunização de idosos com 60 anos ou mais
• DIR Vacina pneumocócica conjugada 13-valente — Doenças pneumocócicas em pacientes de risco
• DIR Vacina Pneumocócica Conjugada 13-valente — Imunização de crianças de até cinco anos de idade contra doença pneumocócica invasiva e pneumonia
• DIR Vacina pneumocócica conjugada 15-valente — Imunização de pacientes de alto risco com ao menos 2 meses de idade contra doença pneumocócica
• DIR Vacina pneumocócica conjugada 20-valente — Imunização de pacientes de alto risco a partir de 5 anos de idade contra doença pneumocócica
• DIR Vacinas pneumocócicas conjugadas — Imunização de crianças até 5 anos de idade contra doença pneumocócica
• DIR Vacina Tetraviral — Para varicela, sarampo, caxumba e rubéola
• DIR Valganciclovir — Profilaxia e tratamento de infecções pelo citomegalovírus (CMV) em pacientes imunossuprimidos pelo HIV
• DIR Washing of HIV positive semen for artificial fertilization: evaluation report
• DIR What is the Antibody Response and Role in Conferring Natural Immunity Following SARS-CoV-2 Infection? Rapid, Living Practice Points from the American College of Physicians
• DIR WHO consolidated guidelines on tuberculosis
• DIR WHO consolidated guidelines on tuberculosis. Module 1
• DIR WHO consolidated guidelines on tuberculosis. Module 2
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 5
• DIR WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia
• DIR WHO guidelines for malaria
• DIR WHO guidelines for malaria, 4 August 2025
• DIR WHO guidelines on meningitis diagnosis, treatment and care
• DIR WHO guidelines on the use of chest imaging in COVID-19
• DIR WHO recommendation on prophylactic antibiotics for women undergoing caesarean section
• DIR WHO recommendation on routine antibiotic prophylaxis for women undergoing operative vaginal birth
• DIR WHO recommendations for management of serious bacterial infections in infants aged 0-59 days

Documentos para Download:

• DIR AAOS/METRC Clinical Practice Guideline on Management of Acute Compartment Syndrome
• DIR AAOS CLINICAL PRACTICE GUIDELINE FOR EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING RECOVERY FROM ADULT ORTHOPAEDIC TRAUMA
• DIR Ácido meso2,3-dimercaptossuccínico (DMSA, succimer) — Intoxicação aguda por mercúrio
• DIR Analysis of the appropiateness of hospital admissions from emergencies
• DIR Analysis of the use of simple cranium, chest and abdomen radiology in emergency hospital services
• DIR Clinical Practice Guideline for the Management of Communication and Swallowing Disorders following Paediatric Traumatic Brain Injury
• DIR Clinical Practice Guidelines for the diagnosis and treatment of non-serious blunt chest trauma
• DIR Cloridrato de hidroxocobalamina na concentração de 5g injetável — Intoxicações por cianeto
• DIR Crisis Intervention for Adults Using a Trauma-Informed Approach: Initial Four Weeks of Management Third Edition
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 1
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 2
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 3
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 4
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 5
• DIR Diretrizes Brasileiras — Diagnostico e Tratamento de Intoxicações por Agrotóxicos – Capítulo 2
• DIR Diretrizes Brasileiras — Diagnósticos e tratamento de intoxicações por agrotóxicos - Capítulo 1
• DIR Diretrizes Brasileiras — Intoxicações por agrotóxicos - Capítulo 3
• DIR Diretrizes Brasileiras — Intoxicações por Agrotóxicos - Capítulo 4
• DIR Diretrizes Brasileiras — Intoxicações por Agrotóxicos - Capítulo 5
• DIR EFNS guideline on mild traumatic brain injury: report of an EFNS task force
• DIR Emergency and acute medical care in over 16s
• DIR Emergency and acute medical care in over 16s: service delivery and organisation
• DIR Hidroxocobalamina na intoxicação aguda por cianeto (Protocolo de Uso)
• DIR Iodeto de Potássio na Emergência Nuclear
• DIR Major trauma: assessment and initial management
• DIR Major trauma: service delivery
• DIR Mild traumatic brain injury
• DIR Monitorização intracraniana PIC Cateter de fibra óptica (tipo CAMINO) — Monitorização da pressão intracraniana em pacientes com traumatismo cranioencefálico grave
• DIR Monitorização intracraniana PIC Cateter PTIO2, cateteres com ponta metálica (tipo CODMAN ou PRESSIO) — Monitorização da pressão intracraniana em pacientes com traumatismo cranioencefálico grave
• DIR Post-traumatic stress disorder
• DIR Rehabilitation after traumatic injury
• DIR STUDY OF URGENT AND EMERGENCY HEALTH SERVICES IN THE BASQUE AUTONOMOUS COMMUNITY: ANALYSIS AND PROPOSALS FOR IMPROVEMENT
• DIR Terapia por pressão subatmosférica (VAC) — Lesões traumáticas agudas extensas
• DIR The experiences of elderly patients receiving care in the emergency department (Best Practice 16(9))
• DIR Trauma

Documentos para Download:

• DIR Exercise for People with Cancer 19-5v2
• DIR Physical activity: brief advice for adults in primary care (PH44)
• DIR Physical activity: encouraging activity in the community
• DIR Physical activity: exercise referral schemes (PH54)
• DIR Physical activity: for NHS staff, patients and carers
• DIR Physical activity: walking and cycling (PH41)
• DIR Physical activity and the environment
• DIR Promoting physical activity for children and young people (PH17)
• DIR Supportive treatment for cancer - Part 1: exercise treatment
• DIR WHO guidelines on physical activity and sedentary behaviour

Documentos para Download:

• PDF Espasticidade – tratamento com nabilone
• PDF Espasticidade – tratamento com glicina e treonina
• PDF Espasticidade – tratamento com Diazepam ou clonazepam
• PDF Espasticidade – tratamento com Baclofeno
• PDF Espasticidade – avaliação pela medida de independência funcional
• PDF Espasticidade – avaliação pela escala de Tardieu
• PDF Espasticidade – avaliação pela escala de reflexos tendinosos
• PDF Espasticidade – tratamento com tizanidina e/ou clonidina
• PDF Espasticidade - Tratamento com Neurólise com fenol
• PDF Espasticidade – avaliação pela escala de penn
• PDF Espasticidade - Tratamento Com Neurólise por Toxina Botulínica
• PDF Espasticidade – tratamento com dantrolene sódico
• PDF Espasticidade – tratamento com piracetem e levetiracetam
• PDF Espasticidade – avaliação pelo índice de barthel
• PDF Espasticidade – avaliação pela escala modificada de ashworth
• PDF Espasticidade – avaliação pela escala analógica de dor
• PDF Úlceras por pressão: tratamento
• DIR AAOS Appropriate Use Criteria for Limb Salvage or Early Amputation
• DIR Baclofeno oral — Tratamento da espasticidade
• DIR Brain injury rehabilitation in adults (SIGN CPG 130)
• DIR Cancer rehabilitation
• DIR EFNS guidelines on cognitive rehabilitation: report of an EFNS task force
• DIR EFNS Guidelines on cognitive rehabilitation: report of an EFNS Task Force
• DIR Espasticidade
• DIR European physiotherapy benchmark statement
• DIR European Physiotherapy Guidelines for Parkinson’s
• DIR Framework for clinical guideline development in physiotherapy
• DIR Management of patients with stroke: rehabilitation, prevention and management of complications, and discharge planning (SIGN CPG 118)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Espasticidade
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Espasticidade
• DIR Quality Assurance Standards of Physiotherapy Practice and Delivery
• DIR Rehabilitation after critical illness in adults
• DIR Rehabilitation after critical illness in adults
• DIR Rehabilitation for adults with complex psychosis
• DIR Spasticity in under 19s: management
• DIR Spinal Cord Injury (SCI). Evidence-Based Nutrition Practice Guideline
• DIR Stroke rehabilitation in adults
• DIR Stroke rehabilitation in adults (CG162)
• DIR Tetraidrocanabinol 27mg/ml + canabidiol 25mg/ml — Espasticidade moderada a grave relacionada à esclerose múltipla

Documentos para Download:

• DIR AAOS Appropriate Use Criteria Anterior Cruciate Ligament Injuries: Prevention Programs
• DIR Ácido fólico 400 mcg + acetato de dextroalfatocoferol 10 mg — Prevenção de distúrbios do tubo neural relacionados a deficiência de ácido fólico, para mulheres em idade fértil
• DIR Alcohol-use disorders - preventing harmful drinking (PH24)
• DIR Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence
• DIR Alcohol-use disorders: diagnosis and management
• DIR Alcohol-use disorders: diagnosis and management of physical complications
• DIR Alcohol-use disorders: physical complications (CG100)
• DIR Alcohol: preventing harmful use in the community
• DIR Alcohol interventions in secondary and further education
• DIR Antisocial personality disorder: prevention and management
• DIR Appropriate Use Criteria: Anterior Cruciate Ligament Injuries: Prevention Programs
• DIR Carbetocina — Prevenção de hemorragia pós-parto
• DIR Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges
• DIR DESIGN AND VALIDATION OF A SCREENING TOOL FOR EVALUATING THE HEALTH IMPACT OF REGIONAL POLICIES
• DIR Drug misuse prevention
• DIR Drug misuse prevention: targeted interventions
• DIR EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis
• DIR EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy
• DIR Evidence-based recommendations for fall prevention
• DIR Fetal alcohol spectrum disorder
• DIR Guidelines for the validation and application of typing methods for use in bacterial epidemiology
• DIR HEALTH PROMOTION. SOME THEORIES AND TOOLS FOR PLANNING AND ASSESSING LIFESTYLE INTERVENTIONS
• DIR Hypothermia: prevention and management in adults having surgery
• DIR Integrating Tobacco Interventions into Daily Practice, Third Edition
• DIR Materiais especiais (almofada de assento com células de ar interconectadas) — Utilizada no assento da cadeira de rodas para prevenção de úlceras de pressão de usuários com alteração da mobilidade e sensibilidade
• DIR Materiais especiais (almofada de assento para cadeira de rodas para a prevenção de úlceras de pressão/simples) — Utilizada no assento da cadeira de rodas para prevenção de úlceras de pressão de usuários com alteração da mobilidade e sensibilidade
• DIR Oral health promotion: general dental practice
• DIR Oral health promotion in the community
• DIR Pain: Prevention, assessment and management, Fourth edition
• DIR Pelvic floor dysfunction: prevention and non-surgical management
• DIR Pressure injury management: Risk assessment, prevention and treatment
• DIR Prevention of preterm birth in women at risk: selected topics
• DIR Recommandations sur le dépistage du retard de développement
• DIR Recommandations sur les interventions comportementales de prévention et de traitement du tabagisme chez les enfants et adolescents d’âge scolaire
• DIR Screening Pelvic Examination in Adult Women: A Clinical Practice Guideline From the American College of Physicians
• DIR Smoking: reducing and preventing tobacco use
• DIR Smoking Cessation Interventions and Strategies (Best Practice 5(3))
• DIR Smoking cessation interventions and strategies (Best Practice 12(8))
• DIR Stop smoking
• DIR Systematic Review and Evidence-Based Guidelines Update for the Role of Audiologic Screening in the Diagnosis and Management of Patients with Vestibular Schwannomas
• DIR The Prevention and Management of Complications associated with PEG Tubes in Adults (Best Practice 14(10))
• DIR Tobacco: preventing uptake, promoting quitting and treating dependence
• DIR Tobacco: treating dependence
• DIR ​Tobacco dependency
• DIR Total fat intake for the prevention of unhealthy weight gain in adults and children
• DIR Treatment of Tobacco Use Disorder
• DIR Unintentional injuries: prevention strategies for under 15s (PH29)
• DIR WHO clinical treatment guideline for tobacco cessation in adults
• DIR WHO Guideline on the prevention of drowning through provision of day-care and basic swimming and water safety skills
• DIR WHO guideline on the prevention of female genital mutilation and clinical management of complications
• DIR WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth
• DIR Woman Abuse: Screening, Identification and Initial Response

Documentos para Download:

• DIR Acetato de Glatirâmer 40mg — Esclerose múltipla remitente recorrente
• DIR Acute stroke treatment in Europe: a questionnaire-based survey on behalf of the EFNS Task Force on acute neurological stroke care
• DIR A European Academy of Neurology guideline on medical management issues in dementia
• DIR Alentuzumabe — Esclerose múltipla remitente recorrente após falha terapêutica a duas ou mais terapias
• DIR Alentuzumabe — Esclerose múltipla remitente recorrente com características comparáveis aos critérios de tratamento com natalizumabe.
• DIR Alentuzumabe — Tratamento da esclerose múltipla remitente recorrente após falha terapêutica com betainterferona ou glatirâmer
• DIR Assessment and Management of Dysphagia in Children with Neurological Impairments (Best Practice 13(1))
• DIR Australian and New Zealand Living Clinical Guidelines for Stroke Management 
• DIR Australian Motor Neurone Disease (MND) Guideline
• DIR Betainterferonas — Esclerose múltipla remitente-recorrente (EMRR)
• DIR Canabidiol — Crianças e adolescentes com epilepsias refratárias aos tratamentos convencionais
• DIR Cladribina oral — Esclerose múltipla remitente-recorrente altamente ativa.
• DIR Cladribina oral — Tratamento de pacientes com esclerose múltipla remitente-recorrente altamente ativa
• DIR Clinical Medication Guidelines for Geriatric Peripheral Neuropathic Pain
• DIR Clinical Practice Guideline for the Management of Cerebral Small Vessel Disease
• DIR Clinical practice guideline for the Management of Patients with Parkinson´s Disease
• DIR Clinical Practice Guideline for the Prevention and/or Treatment of Chemotherapy-Induced Peripheral Neuropathy using Natural Health Products
• DIR Clinical practice guidelines for surgery in patients with tuberous sclerosis complex-related epilepsy
• DIR Clinical Practice Guidelines for The Diagnosis and Treatment of Diffuse Glioma-Related Epilepsy: 2025 update
• DIR Cloridrato de fingolimode — Primeira linha de pacientes com esclerose múltipla remitente recorrente, de baixa e moderada atividade, em troca entre os medicamentos de primeira linha ou virgens de tratamento
• DIR Cloridrato de memantina — Alzheimer moderada e grave em pacientes com disfagia
• DIR Clozapina — Psicose associada à doença de Parkinson
• DIR Composto nutricional — Melhora de memória em pacientes com doença de Alzheimer na fase leve
• DIR DESIGN OF AN INTERACTION PROTOCOL BETWEEN PRIMARY CARE AND HOSPITALS TO IMPROVE EARLY DETECTION AND MONITORING OF PATIENTS WITH MULTIPLE SCLEROSIS
• DIR Diagnosis and drugs consumption for Alzheimer's disease in the Basque Country
• DIR Diagnosis and management of epilepsy in adults (SIGN CPG 143)
• DIR Dicloridrato de pramipexol — Liberação prolongada para parkinson idiopática em fase inicial ou avançada
• DIR Doença de Alzheimer
• DIR Doença de Parkinson
• DIR Donepezila — Pacientes com doença de Alzheimer grave
• DIR Duloxetina — Dor neuropática e da fibromialgia
• DIR EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke
• DIR EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke
• DIR EAN guideline on palliative care of people with severe, progressive multiple sclerosis
• DIR EAN guideline on palliative care of people with severe, progressive multiple sclerosis
• DIR EAN guideline on palliative care of people with severe, progressive multiple sclerosis
• DIR EAN guidelines on central neurostimulation therapy in chronic pain conditions
• DIR ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
• DIR ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
• DIR EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease
• DIR EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease
• DIR EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force
• DIR EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force
• DIR EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force
• DIR EFNS guideline on the management of status epilepticus
• DIR EFNS guideline on the management of status epilepticus in adults
• DIR EFNS guideline on the treatment of tension-type headache – Report of an EFNS task force
• DIR EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses
• DIR EFNS guidelines for the diagnosis and management of Alzheimer’s disease
• DIR EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases
• DIR EFNS guidelines on management of narcolepsy
• DIR EFNS guidelines on neuropathic pain assessment: revised 2009
• DIR EFNS guidelines on neurostimulation therapy for neuropathic pain
• DIR EFNS guidelines on pharmacological treatment of neuropathic pain
• DIR EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force
• DIR EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias
• DIR EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias
• DIR EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
• DIR EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis
• DIR EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
• DIR EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
• DIR EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives
• DIR EFNS task force on molecular diagnosis of neurologic disorders Guidelines for the molecular diagnosis of inherited neurologic diseases First of two parts
• DIR EFNS task force on molecular diagnosis of neurologic disorders Guidelines for the molecular diagnosis of inherited neurologic diseases Second of two parts
• DIR EFNS Task Force on postgraduate neurological training Survey of the current situation of postgraduate neurological training in Europe
• DIR EFNS Task Force on Teaching of Neuroimaging in Neurology Curricula in Europe: present status and recommendations for the future
• DIR Epilepsia
• DIR Epilepsies in children, young people and adults
• DIR Epilepsies in children, young people and adults
• DIR Epilepsies in children and young people: Investigative procedures and management (SIGN CPG 159)
• DIR Esclerose Múltipla
• DIR Estimulação elétrica do nervo vago — Terapia adjuvante de pacientes pediátricos com epilepsia resistente a medicamentos, sem indicação para cirurgia ressectiva de epilepsia
• DIR Estimulação elétrica do nervo vago na terapia adjuvante — Farmacológico em crianças e adultos com epilepsia focal ou generalizada refratária a pelo menos dois esquemas com medicamentos anticonvulsivantes para epilepsia
• DIR European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO‐NMD)
• DIR European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies
• DIR European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision
• DIR European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome
• DIR European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome
• DIR European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke
• DIR European Academy of Neurology guideline on the diagnosis of coma and other disorders of consciousness
• DIR European Academy of Neurology guideline on the management of medication-overuse headache
• DIR European Academy of Neurology guideline on trigeminal neuralgia
• DIR European Academy of Neurology guidelines on the treatment of cluster headache
• DIR European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher
• DIR European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher
• DIR European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy*
• DIR European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Socie
• DIR European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Ne
• DIR European guideline and expert statements on the management of narcolepsy in adults and children
• DIR European guideline and expert statements on the management of narcolepsy in adults and children
• DIR European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society
• DIR European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment
• DIR Fingolimode — Esclerose múltipla
• DIR Fingolimode — Esclerose múltipla
• DIR Fingolimode — Esclerose múltipla remitente recorrente após falha terapêutica com betainterferona ou glatirâmer
• DIR Fumarato de dimetila — Esclerose múltipla remitente-recorrente após a 1ª falha terapêutica
• DIR Fumarato de dimetila — Esclerose múltipla remitente recorrente após falha com betainterferona ou glatirâmer
• DIR Fumarato de dimetila — Primeira linha da esclerose múltipla remitente recorrente
• DIR Guidance for the preparation of neurological management guidelines by EFNS scientific task forces
• DIR Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004*
• DIR Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2012
• DIR Guidelines by the European Federation of Neurological Societies (EFNS) subcommittee for Continuing Medical Education (CME) – modification 2003
• DIR Guidelines for Specialized Epilepsy Centers. Executive Summary of the Report of the National Association of Epilepsy Centers Guideline Panel
• DIR Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-B antibodies in multiple sclerosis
• DIR Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis
• DIR ​Headache in adult
• DIR Headaches in over 12s
• DIR Headaches in over 12s: diagnosis and management
• DIR Identification and Management of Dysphagia in Children with Neurological Impairment (Best Practice 4(3))
• DIR Joint European Academy of Neurology–European Pain Federation–Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment
• DIR KNGF Guideline for Physical Therapy in patients with Parkinson's disease
• DIR Lacosamida — Terapia aditiva em pacientes com epilepsia focal refratários aos tratamentos prévios com os fármacos antiepilépticos disponíveis no SUS
• DIR Levetiracetam (500 mg e 1000 mg) — Tratamento adjuvante para epilepsia
• DIR Levetiracetam — Convulsões em pacientes com microcefalia
• DIR Levetiracetam — Epilepsia
• DIR Levetiracetam — Terapia adjuvante em pacientes com epilepsia mioclônica juvenil resistentes à monoterapia
• DIR Levetiracetam em monoterapia — Epilepsia focal em pacientes com falha no tratamento com carbamazepina
• DIR Lidocaína — Dor neuropática localizada
• DIR Management of Ischaemic Stroke (2nd Edition)
• DIR Management of Multiple Sclerosis
• DIR Management of paraneoplastic neurological syndromes: report of an EFNS Task Force
• DIR Memantina — Doença de Alzheimer
• DIR Mesilato de bromocriptina — Doença de Parkinson e de hiperprolactinemia.
• DIR Mesilato de rasagilina em combinação com levodopa — Doença de Parkinson com complicações motoras
• DIR Miglustate — Manifestações Neurológicas da Doença de Niemann-Pick Tipo C (NPC)
• DIR Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas: Guideline From the College of American Pathologists in Collaboration With the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology
• DIR Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology
• DIR Monogenic cerebral small‐vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology
• DIR Motor neurone disease
• DIR Motor neurone disease: assessment and management
• DIR Multiple sclerosis
• DIR Multiple sclerosis in adults: management
• DIR Natalizumabe — Esclerose múltipla remitente-recorrente com alta atividade de doença
• DIR Natalizumabe 300mg — Esclerose múltipla
• DIR National clinical guideline for stroke for the UK and Ireland (SIGN CPG 166)
• DIR Neuropathic pain in adults: pharmacological management in non-specialist settings
• DIR Neurophysiological tests and neuroimaging procedures in non-acute headache: guidelines and recommendations
• DIR Ocrelizumabe — Adultos com esclerose múltipla remitente-recorrente (EMRR) como alternativa ou contraindicação ao natalizumabe
• DIR Ocrelizumabe — Esclerose Múltipla primariamente
• DIR Ocrelizumabe — Recorrencia de Esclerose Múltipla
• DIR Ofatumumabe em primeira linha de terapia modificadora do curso da doença — Tratamento da esclerose múltipla recorrente
• DIR Parkinson's disease
• DIR Parkinson's disease in adults
• DIR PET Imaging in Paraneoplastic Neurological Syndromes 18
• DIR Pharmacological management of migraine (SIGN CPG 155)
• DIR Pharmacological treatment of migraines. Qualitative study
• DIR Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians
• DIR Pregabalina — Dor neuropática e fibromialgia
• DIR Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
• DIR Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Alzheimer
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Alzheimer
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Parkinson
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Parkinson
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Epilepsia
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR QUALITY OF LIFE OF STROKE PATIENTS AND THEIR CAREGIVERS. PROGNOSIS AND RESULTS OF REHABILITATING TREATMENT
• DIR Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
• DIR Report of an EFNS task force on management of sleep disorders in neurologic disease (degenerative neurologic disorders and stroke)
• DIR Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's dise
• DIR Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease
• DIR Rivastigmina — Doença de Parkinson e demência
• DIR Rivastigmina adesivo transdérmico — Demência para Doença de Alzheimer
• DIR Rivastigmina via transdérmica (adesivo) — Demência leve e moderadamente grave do tipo Alzheimer
• DIR Selegilina — Doença de Parkinson
• DIR Selegilina 10 mg — Doença de Parkinson
• DIR Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
• DIR Stroke in adults
• DIR Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
• DIR Suspected neurological conditions: recognition and referral
• DIR Suspected neurological conditions: recognition and referral
• DIR Systematic Review and Evidence-Based Guidelines for Occipital Nerve Stimulation for the Treatment of Patients With Medically Refractory Occipital Neuralgia Update
• DIR Teriflunomida — Primeira linha de tratamento da esclerose múltipla remitente recorrente
• DIR The Diagnosis & Management of Stroke and Transient Ischaemic Attack
• DIR The Utility of Positron Emission Tomography in Epilepsy 13
• DIR Tolcapona 100 mg — Doença de Parkinson
• DIR Traditional Chinese Medicine treatment guideline for primary headache disorders(NGC: 011363)
• DIR Treatment of medication overuse headache – guideline of the EFNS headache panel
• DIR Treatment of miscellaneous idiopathic headache disorders (group 4 of the IHS classification) – Report of an EFNS task force
• DIR When to order CT/MRI for headache

Documentos para Download:

• PDF Avaliação da Composição Corporal por Bioimpedanciometria
• PDF Avaliação nutrológica – nutroterapia intrahospitalar
• PDF Avaliação nutrológica – monitorização da composição corporal
• PDF Avaliação nutrológica – monitorização ambulatorial da mobilidade (mam)
• PDF Avaliação nutrológica – ergometria modal
• PDF Dismenorreia primária tratamento
• DIR Academy of Nutrition and Dietetics Evidence Analysis Manual
• DIR Adult Weight Management (AWM). Evidence Based Nutrition Practice Guideline
• DIR Alimento para nutrição enteral ou oral — Nutrição enteral ou oral no pré-operatório de cirurgias oncológicas gastrointestinais eletivas de grande porte
• DIR Australian Dietary Guidelines (2013) (N 55)
• DIR Bladder cancer. National consensus-based nutrition guideline
• DIR Congress of Neurological Surgeons Systematic Review and Evidence-based Guidelines for Perioperative Spine: Preoperative Nutritional Assessment
• DIR Critical Illness. Evidence-Based Nutrition Practice Guideline
• DIR Effective dietary interventions for overweight and obese children (Best Practice 11(1))
• DIR Esophagus cancer nutrition
• DIR Food and Nutrition for Older Adults Promoting Health and Wellness Recommendations (FNOA)
• DIR General Nutrition and Dietary treatment
• DIR Guideline: fortification of wheat flour with vitamins and minerals as a public health strategy
• DIR Lung cancer. National consensus-based nutrition guideline
• DIR Maternal and child nutrition (PH11)
• DIR Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years
• DIR Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years (NG247)
• DIR Neonatal parenteral nutrition
• DIR Neonatal parenteral nutrition
• DIR Nutrition and dietary therapy for lungcancer (english version). National nutrition consensus guideline
• DIR Nutrition in patients with gastric cancer
• DIR Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
• DIR Nutrition support in adults
• DIR Oncology (ONC). Evidence-based Nutrition Practice Guideline
• DIR Oral liquid nutritional supplements for people with dementia in residential aged care facilities (Best Practice 14(3))
• DIR Pancreatic cancer nutrition
• DIR Pediatric Weight Management (PWM). Evidence-Based Nutrition Practice Guideline
• DIR Prostatic cancer nutrition
• DIR Suplementação nutricional oral — Clínicos ou cirúrgicos desnutridos ou em risco de desnutrição
• DIR The Recognition, Prevention and Management of Vitamin D Deficiency in Children and Adults
• DIR Unintended Weight Loss (UWL) in Older Adults. Evidence-based Nutrition Practice Guideline
• DIR VALIDATION OF A MALNUTRITION SCREENING TOOL USEFUL IN A GENERAL HOSPITAL
• DIR Vegetarian Nutrition (VN). Evidence-Based Nutrition Practice Guideline
• DIR Vitamin B12 deficiency in over 16s: diagnosis and management
• DIR Vitamin D: supplement use in specific population groups (PH56)
• DIR WHO guideline on the dairy protein content in ready-to-use therapeutic foods for treatment of uncomplicated severe acute malnutrition
• DIR WHO guideline on the prevention and management of wasting and nutritional oedema (acute malnutrition) in infants and children under 5 years

Documentos para Download:

• DIR Abemaciclibe — Adultas com câncer de mama avançado ou metastático com HR+ e HER2-
• DIR Abirateron — Câncer de próstata metastático resistente à castração em pacientes com uso prévio de quimioterapia
• DIR Abiraterona associada à terapia de privação androgênica (TPA) — Câncer de próstata resistente à castração, metastático e virgens de quimioterapia.
• DIR Abiraterona em monoterapia ou associada ao docetaxel — Câncer de próstata sensível à castração e metastático.
• DIR Ablação térmica — Metástase hepática irressecável ou ressecável com alto risco cirúrgico do câncer de cólon e reto
• DIR Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
• DIR Active Surveillance for the Management of Localized Prostate Cancer 17-9
• DIR Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement
• DIR Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small Cell Lung Cancer
• DIR Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
• DIR Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
• DIR Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline
• DIR Alectinibe — Câncer de pulmão de células não pequenas localmente avançado ou metastático cujos tumores expressam rearranjo no gene ALK em pacientes não tratados previamente ou após falha com crizotinibe
• DIR Alectinibe — Câncer de pulmão não pequenas células com translocação em ALK em estágio localmente avançado ou metastático como primeira linha de tratamento
• DIR American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
• DIR American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
• DIR American Society of Clinical Oncology Endorsement: Guideline for the Management of Fever and Neutropenia in Children with Cancer and or Undergoing Hematopoietic Stem Cell Transplantation
• DIR Analysis and review of protocols and quality standards in the diagnostic process for the detection of cervical cancer
• DIR A national clinical practice guideline on the management of localised prostate cancer
• DIR Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines
• DIR Anticorpos monoclonais (bevacizumabe, cetuximabe, panitumumabe) associados à quimioterapia — Tratamento de primeira linha do câncer colorretal metastático
• DIR Apalutamida, darolutamida e enzalutamida (associados à TPA) — Câncer de próstata resistente à castração não metastático
• DIR Apalutamida — Câncer de próstata sensível à castração e metastático.
• DIR Approach to fever assessment in ambulatory cancer patients receiving chemotherapy 12-15
• DIR Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update
• DIR ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males with Germ Cell Tumors
• DIR Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours
• DIR Bevacizumabe — Câncer de Colo de Útero Persistente, Recorrente ou Metastático
• DIR Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
• DIR Biomarkers for Systemic Therapy in Metastatic Breast Cancer
• DIR Bladder cancer
• DIR Bladder cancer: an assessment of international practice guidelines
• DIR Bladder cancer: diagnosis and management
• DIR Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline
• DIR Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update
• DIR Brain tumours (primary) and brain metastases in over 16s
• DIR Brain tumours (primary) and brain metastases in over 16s
• DIR Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update
• DIR Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.
• DIR Brigatinibe — Câncer de pulmão não pequenas células com translocação em ALK em estágio localmente avançado ou metastático como primeira linha de tratamento
• DIR Cabozantinibe — Segunda linha para pacientes com carcinoma de células renais metastático
• DIR Câncer de Pulmão
• DIR Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over
• DIR Cancer services for children and young people
• DIR Cancer survivorship care
• DIR Carcinoma de Células Renais
• DIR Carcinoma de Esôfago
• DIR Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
• DIR Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society
• DIR Cetuximabe — Câncer colorretal metastático RAS selvagem com doença limitada ao fígado em primeira linha
• DIR Cetuximabe — Câncer de cabeça e pescoço metastático
• DIR Cetuximabe — Carcinoma espinocelular de cabeça e pescoço recidivado ou metastático
• DIR Cetuximabe — Tratamento em primeira linha de pacientes com câncer colorretal metastático com expressão de EGFR, sem mutação do gene RAS
• DIR Cetuximabe em combinação com FOLFIRI ou FOLFOX — Câncer colorretal metastático KRAS selvagem com metástases hepáticas exclusivas irresecáveis
• DIR Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline
• DIR Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
• DIR Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
• DIR Citologia em meio líquido — Rastreamento de câncer de colo de útero e lesões precursoras
• DIR Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline
• DIR Clinical practice guidelines for keratinocyte cancer
• DIR Clinical Practice Guidelines for the Early Diagnosis and Management of Early-Onset Colorectal Cancer
• DIR Cloridrato de erlotinibe — Câncer de pulmão de células não-pequenas avançado ou metastático mutação EGFR
• DIR Colon Cancer :Diagnosis, Treatment and Follow-Up
• DIR Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society
• DIR Continuous versus Intermittent Chemotherapy Strategies in Inoperable, Advanced Colorectal Cancer 2-6v2
• DIR CPOE in the Outpatient Oncology Setting 12-14
• DIR Criteria for appropriate use of FDG-PET in esophageal cancer
• DIR Crizotinibe — Tratamento, em primeira linha, de pacientes adultos com câncer de pulmão não pequenas células (CPNPC) avançado ALK+
• DIR Darolutamida — Câncer de próstata sensível à castração e metastático.
• DIR Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
• DIR Diretrizes Brasileiras — Rastreamento do Câncer de Colo do Útero: Parte I - Rastreamento organizado utilizando testes moleculares para detecção de DNA-HPV Oncogênico
• DIR Diretrizes Diagnósticas e Terapêuticas — Carcinoma de Células Renais
• DIR Diretrizes Diagnósticas e Terapêuticas — Tumor Cerebral no Adulto
• DIR Duration of Oxaliplatin-containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline
• DIR Durvalumabe — Câncer de pulmão Não pequenas células (CPNPC) estágio III irressecável, cuja doença Não progrediu após a terapia de quimiorradiação à base de platina
• DIR E-health systems to support cancer patients: proposal for the design of future assessment studies
• DIR EAES Rapid Guideline: Complete mesocolic excision for right-sided colon cancer
• DIR Ecobroncoscopia e ecoendoscopia em uso combinado, ou ecobroncoscopia em uso isolado — Pacientes diagnosticados com câncer de pulmão
• DIR Effective communication between registered nurses and adult oncology patients in inpatient settings (Best Practice 15(1))
• DIR Effectiveness and safety of bone suppression technology for the detection of lung cancer and indications for its use
• DIR Effective Teaching Strategies and Methods for Cancer Patient Education 20-2v2
• DIR Effective Use of Advanced Practice Nurses in the Delivery of Adult Cancer Services in Ontario 16-4
• DIR EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force
• DIR Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
• DIR Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Guideline and Rapid Update
• DIR Endorsement of the European Association of Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas 11-6v2
• DIR Enhancing the quality of information on colorectal and prostate cancer in the population cancer register of the Basque Country (RCE) and bibliographical review
• DIR Enzalutamida — Câncer de próstata resistente à castração metastático virgens de quimioterapia
• DIR Enzalutamida — Câncer de próstata sensível à castração e metastático.
• DIR Enzalutamida associada à TPA — Câncer de próstata resistente à castração metastático com uso prévio de docetaxel
• DIR EPIDEMIOLOGICAL ANALYSIS OF INFORMATION COLLECTED BY HOSPITAL CANCER REGISTRIES IN THE BASQUE AUTONOMOUS COMMUNITY IDENTIFICATION OF POSSIBLE IMPROVEMENTS WITH REGARD TO THE FEEDBACK AND DISSEMINATION OF RESULTS
• DIR Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion
• DIR Evidence-Based Clinical Practice Guidelines for Microcystic Adnexal Carcinoma Informed by a Systematic Review
• DIR Exclusão do crizotinibe — Pacientes adultos com câncer de pulmão não pequenas células (CPNPC) avançado ou metastático ALK+
• DIR Expert Consensus on Rapid On-Site Evaluation in Diagnostic Interventional Pulmonology
• DIR Expert consensus on risk assessment and early screening for invasive fungal disease in adult patients with cancer
• DIR Fear of Cancer Recurrence Guideline 19-7
• DIR Fertility Preservation in Patients with Cancer: American Society of Clinical Oncology Guideline Update
• DIR Focal Tumour Ablation: Early-stage Primary Lung Cancer and Lung Metastases 4
• DIR Follow-up after primary therapy for endometrial cancer 4-9v2
• DIR Follow-up and Surveillance of Curatively Treated Lung Cancer Patients 26-3v2
• DIR Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement
• DIR Follow-up Care and Psychosocial Needs of Survivors of Prostate Cancer 26-4
• DIR Follow-up for Cervical Cancer 4-16v3
• DIR Gastric carcinoma
• DIR Gefitinibe — Câncer de pulmão de células não pequenas avançado ou metastático com mutação EGFR, em primeira linha
• DIR GENETIC COUNSELLING IN BREAST CANCER AND COLON CANCER
• DIR Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
• DIR Guideline for preventive chemotherapy for the control of Taenia solium taeniasis
• DIR Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
• DIR Guidelines on Management of Nausea and Vomiting and on Loss of Appetite, Anorexia, and Cachexia in Cancer
• DIR Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline
• DIR Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline
• DIR Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
• DIR Human Papillomavirus Testing in Head and Neck Carcinomas
• DIR Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
• DIR Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation
• DIR Improving outcomes for people with brain and other central nervous system tumours (CSG10)
• DIR Improving outcomes for people with sarcoma (CSG9)
• DIR Improving outcomes in children and young people with cancer (CSG7)
• DIR Improving outcomes in urological cancers (CSG2)
• DIR Improving supportive and palliative care for adults with cancer (CSG4)
• DIR Inibidores de tirosina quinase — Câncer de pulmão não pequenas células com translocação de ALK, localmente avançado ou metastático, em segunda linha de tratamento
• DIR Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer
• DIR Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
• DIR Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First Line Chemotherapy 7-13v2
• DIR Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
• DIR INTERVAL CANCERS IN THE EARLY BREAST CANCER DETECTION PROGRAMME
• DIR Interventions to Address Sexual Problems in People with Cancer 19-6
• DIR Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline
• DIR Invasive Mediastinal Staging of Non-small Cell Lung Cancer 17-6V2
• DIR Ipilimumabe + nivolumabe — Primeira linha de câncer de células renais
• DIR Ipilimumabe — Melanoma metastático com progressão após quimioterapia
• DIR Ixequizumabe — Adultos com espondiloartrite axial com resposta prévia inadequada ou intolerância aos inibidores do fator de necrose tumoral
• DIR Laringe eletrônica — Neoplasia maligna da laringe
• DIR Larotrectinibe — Pacientes pediátricos com tumores sólidos localmente avançados ou metastáticos positivos para fusão do gene NTRK
• DIR Larotrectinibe — Tumores sólidos localmente avançados ou metastáticos positivos para fusão do gene NTRK
• DIR Lenvatinibe — Carcinoma diferenciado da tireoide localmente avançado e/ou metastático, refratário ao iodo, progressivo
• DIR Leptomeningeal metastases
• DIR Linfadenectomia seletiva guiada — Oncologia
• DIR Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
• DIR Long term follow up of survivors of childhood cancer (SIGN CPG 132)
• DIR Lorlatinibe — Câncer de pulmão não pequenas células com translocação em ALK em estágio localmente avançado ou metastático como primeira linha de tratamento
• DIR Lung cancer: diagnosis and management
• DIR Lung cancer in adults
• DIR Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline
• DIR Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline
• DIR Management of adult testicular germ cell tumours (SIGN CPG 124)
• DIR Management of Cancer Cachexia: ASCO Guideline
• DIR Management of Cancer Cachexia: Rapid Update
• DIR Management of Cancer Pain
• DIR Management of Cervical Cancer (Second Edition)
• DIR Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
• DIR Management of Dyspnea in Advanced Cancer: ASCO Guideline
• DIR Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
• DIR Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
• DIR Management of lung cancer (SIGN CPG 137)
• DIR Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
• DIR Management of Nasopharyngeal Carcinoma
• DIR Management of pancreatic cancer: capita selecta
• DIR Management of primary cutaneous squamous cell carcinoma (SIGN CPG 140)
• DIR Management of Salivary Gland Malignancy: ASCO Guideline
• DIR Management of Squamous Cell Cancer of the Anal Canal 2-8v2
• DIR Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and the American Society of Clinical Oncology Joint Guideline 1-23-A
• DIR Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline
• DIR Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology Consensus Guideline
• DIR Mesilato de imatinibe — Quimioterapia adjuvante do tumor do estroma gastrointestinal
• DIR Metastatic malignant disease of unknown primary origin in adults: diagnosis and management
• DIR Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
• DIR Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)
• DIR Models of Care for Cancer Survivorship 26-1v2
• DIR Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology
• DIR Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
• DIR Molecular Testing for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the CAP/IASLC/AMP Guideline
• DIR Monitorização Intraoperatória Neurofisiológica — Pacientes com tumor cerebelopontino submetidos à cirurgia de exérese tumoral com alto risco de sequelas neurológicas
• DIR Musculoskeletal Tumor Society Clinical Practice Guideline on the Management of Metastatic Humeral Disease
• DIR National practice guideline on the treatment of localised prostate cancer – part 2
• DIR Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma 4-1v2
• DIR Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
• DIR Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
• DIR Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
• DIR Niraparibe — Manutenção de pacientes adultas com carcinoma de ovário (incluindo trompa de Falópio ou peritoneal primário), de alto grau (grau 2 ou maior), avançado (estágio FIGO III ou IV), com mutação nos genes BRCA 1/2, que respondem à quimioterapia em
• DIR Nivolumabe — Adultos com câncer de estômago ou da junção esofagogástrica, avançado ou metastático não tratados anteriormente
• DIR Nivolumabe — Adultos com carcinoma espinocelular de cabeça e pescoço recidivado ou metastático após quimioterapia à base de platina (i.e., segunda linha de tratamento da doença recidivado ou metastática).
• DIR Nivolumabe — Segunda linha para pacientes com carcinoma de células renais metastático
• DIR Nivolumabe — Tratamento adjuvante de pacientes adultos com diagnóstico confirmado de carcinoma de esôfago após tratamento trimodal (quimioterapia, radioterapia e cirurgia)
• DIR Nivolumabe e o pembrolizumabe — Primeira linha do carcinoma de esôfago avançado ou metastático em pacientes com maior expressão de PD-L1
• DIR Non-pharmacological interventions for cancer-related fatigue in men treated for prostate cancer (Best Practice 16(12))
• DIR Non-Small Cell and Small Cell Lung Cancer: Diagnosis, Treatment and Follow-up
• DIR Oesophago-gastric cancer
• DIR Oesophago-gastric cancer: assessment and management in adults
• DIR Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
• DIR Oral cavity cancer: diagnosis, treatment and follow-up
• DIR Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update
• DIR Palbociclibe — Adultas com câncer de mama avançado ou metastático com HR+ e HER2-
• DIR Palliative care requirements in the case of non-oncological diseases. A qualitative study from the perspective of professionals, patients and carers
• DIR Pancreatic cancer
• DIR Pancreatic cancer in adults: diagnosis and management
• DIR Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
• DIR Patient safety issues: key components of chemotherapy labelling 12-11v2
• DIR PD-L1 and TMB Testing of Patients with Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies
• DIR Pembrolizumabe + axitinibe — Primeira linha de câncer de células renais
• DIR Pembrolizumabe — Câncer de pulmão não pequenas células avançado ou metastático
• DIR Pembrolizumabe — Carcinoma espinocelular de cabeça e pescoço recidivado ou metastático
• DIR Pembrolizumabe em primeira linha — Câncer de cólon e reto metastático e alta instabilidade de microssatélite
• DIR Pertuzumabe — Câncer de mama HER2-positivo metastático em primeira linha de tratamento associado ao trastuzumabe e docetaxel
• DIR Pertuzumabe em combinação com trastuzumabe e quimioterapia — Tratamento neoadjuvante de pacientes com câncer de mama HER2-positivo inicial
• DIR Pertuzumabe e trastuzumabe em dose fixa subcutânea — Metastático de pacientes com câncer de mama HER2-positivo em primeira linha
• DIR PET-CT — Detecção de metástase de câncer colorretal, exclusivamente hepática e potencialmente ressecável
• DIR PET-CT — Estadiamento de pacientes com doença localmente avançada de carcinoma de esôfago não sabidamente metastático (após resultados inconclusivos na TC)
• DIR PET Imaging in Anal Canal Cancer 17
• DIR PET Imaging in Brain Cancer 10
• DIR PET Imaging in Cervical Cancer 6
• DIR PET Imaging in Esophageal Cancer 4v2
• DIR PET Imaging in Pancreatic Cancer 5
• DIR PET Imaging in Small Cell Lung Cancer 9
• DIR PET Imaging in Testicular Cancer 8
• DIR Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
• DIR Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline
• DIR Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
• DIR Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology
• DIR Preoperative or Postoperative Therapy for Resectable Esophageal Cancer 2-11v4
• DIR Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
• DIR Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
• DIR Primary Treatment for Locally Advanced Cervical Cancer: Concurrent Platinum-based Chemotherapy and Radiation 4-5
• DIR Procedimento - Quimioterapia Adjuvante — Carcinoma Epidermoide de cabeça e pescoço
• DIR Procedimentos de hormonioterapia adjuvante à radioterapia externa — Câncer de próstata
• DIR Procedimentos de hormonioterapia prévia à radioterapia externa — Câncer de próstata
• DIR Prostate cancer
• DIR Prostate cancer: diagnosis and management
• DIR Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement
• DIR Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline
• DIR Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
• DIR Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline
• DIR Ramucirumabe — Adultos diagnosticados com câncer de estômago ou junção gastroesofágica avançado ou metastático refratários à primeira linha de tratamento
• DIR Rastreamento do Câncer do Colo do Útero (Diretriz Brasileira)
• DIR Recommandations concernant le dépistage du cancer du sein chez les femmes de 40 à 74 ans qui ne sont pas à risque accru de cancer du sein
• DIR Recommandations sur le dépistage du cancer du poumon
• DIR Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
• DIR Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
• DIR Recommendations on screening for cervical cancer
• DIR Referral of Suspected Prostate Cancer by Family Physicians and Other Primary Care Providers 24-3v2
• DIR Regorafenibe — Tumor do estroma gastrointestinal avançado ou metastático, após falha ao imatinibe e sunitinibe
• DIR Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma 2-33v2
• DIR Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update
• DIR Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline
• DIR Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion
• DIR RT-PCR — Identificação de mutação do receptor do fator de crescimento epidérmico (EGFR) em pacientes com câncer de pulmão de células não pequenas
• DIR Safe Administration of Chemotherapy: Methods and Development 12-12M
• DIR Safe administration of systemic cancer therapy.Part 2: Administration of chemotherapy and management of preventable adverse event. 12-12-2v2
• DIR Safe Administration of Systemic Cancer Therapy Part 1: Safety During Chemotherapy Ordering, Transcribing, Dispensing, and Patient Identification 12-12-1
• DIR Salivary Gland Hypofunction and/or Xerostomia Induced by Non-Surgical Cancer Therapies
• DIR Sarcoma
• DIR Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation
• DIR Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation
• DIR Sebaceous Carcinoma: Evidence-Based Clinical Practice Guidelines
• DIR Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion
• DIR Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline
• DIR Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Rapid Update
• DIR Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
• DIR Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update
• DIR Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
• DIR Sentinel Lymph Node Biopsy in Vulvar Cancer 4-17v2
• DIR Sequenciamento de Nova Geração — Identificação de mutação nos genes BRCA1/2 em mulheres com câncer
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse event
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
• DIR Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
• DIR Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ
• DIR Sorafenibe — Carcinoma diferenciado da tireoide localmente avançado e/ou metastático, refratário ao iodo, progressivo
• DIR Spinal metastases and metastatic spinal cord compression
• DIR Spinal metastases and metastatic spinal cord compression
• DIR Staging and Surgical Approaches in Gastric Cancer 2-19
• DIR Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline
• DIR Succinato de ribociclibe — Adultas com câncer de mama avançado ou metastático com HR+ e HER2-
• DIR Sunitinibe — Indivíduos com tumor do estroma gastrointestinal avançado ou metastático, após falha ao imatinibe e sunitinibe
• DIR Sunitinibe ou pazopanibe — Portadores de carcinoma renal de células claras metastático
• DIR Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy
• DIR Supportive treatment for cancer – Part 3: Treatment of pain: most common practices
• DIR Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours 7-11v3
• DIR Suspected cancer: recognition and referral
• DIR Systematic Review and Evidence-Based Guidelines Update for the Role of Emerging Therapies in the Management of Patients with Metastatic Brain Tumors
• DIR Systemic Therapy for Advanced Gastric and Gastro-Esophageal Carcinoma 2-26 v3
• DIR Systemic therapy for advanced or recurrent endometrial cancer, and advanced or recurrent uterine papillary serous carcinoma 4-8v4
• DIR Systemic Therapy for Metastatic Urothelial Cancer: An Endorsement of a Portion of the European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer
• DIR Systemic therapy for recurrent, metastatic, or persistent cervical cancer 4-20v2
• DIR Systemic therapy for unresectable advanced or metastatic pancreatic and midgut neuroendocrine tumours: Version 2 2-21v2
• DIR Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC) Guideline and Rapid Update
• DIR Systemic therapy in men with metastatic castration-resistant prostate cancer 3-15v2
• DIR Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
• DIR Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer 7-22
• DIR Testagem Molecular — Detecção de HPV e rastreamento do câncer do colo do útero
• DIR The decisional process for the choice of active surveillance in localized prostate cancer
• DIR The effectiveness and safety of different forms of treating prostate cancer
• DIR The Management of Depression in Patients with Cancer 19-4v2
• DIR The prevention and treatment of oral mucositis in cancer patients (Best Practice 2(3))
• DIR Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO Guideline
• DIR Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) Joint Guideline Update 7-A-2018-3
• DIR Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
• DIR Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
• DIR Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations
• DIR Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations
• DIR The Role of Endolaryngeal Surgery (With or Without Laser) versus Radiotherapy in the Management of Early (T1) Glottic Cancer 5-2v2
• DIR The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement 2-31
• DIR The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
• DIR The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
• DIR The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
• DIR The Treatment of Metastatic Carcinoma and Myeloma of the Femur: Clinical Practice Guideline
• DIR The use of systemic treatment in the maintenance of patients with non-small cell lung cancer
• DIR The use of targeted therapies in patients with inoperable locally advanced or metastatic renal cell cancer 3-8-4v2
• DIR The Utility of PET/CT in Colorectal Cancer Metastasis: An Evidence Summary 15
• DIR Tomografia computadorizada por emissão de pósitrons — Pacientes com câncer de pulmão de células pequenas
• DIR Tomografia por Emissão de Pósitrons (PET-CT) — Câncer de mama metastático (quando os exames de imagem convencionais apresentarem achados equívocos)
• DIR Trastuzumabe — Adultos com câncer de estômago ou da junção esofagogástrica, avançado ou metastático, HER2+ e não tratados anteriormente (1ª linha)
• DIR Trastuzumabe entansina em monoterapia — Tratamento de pacientes com câncer de mama HER2-positivo metastático ou localmente avançado iressecável, com tratamento prévio de trastuzumabe e um taxano
• DIR Treatment for Brain Metastases: ASCO Guideline
• DIR Treatment of Locally Advanced Esophageal Carcinoma
• DIR Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline
• DIR Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
• DIR Treatment of Metastatic Colorectal Cancer: ASCO Guideline
• DIR Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline
• DIR Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
• DIR Tumor Cerebral no Adulto (DDT)
• DIR Tumour markers in certain cancer locations
• DIR Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
• DIR Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
• DIR Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline—Integration of Results From TAILORx
• DIR Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
• DIR Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
• DIR Vismodegibe — Carcinoma basocelular localmente avançado ou metastático sem indicação de cirurgia e radioterapia
• DIR Vulvar neoplasms
• DIR WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention
• DIR WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention
• DIR WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention
• DIR WHO guideline on preventive chemotherapy for public health control of strongyloidiasis